An encouraging preclinical evidence with the H3R antagonist ABT-239 suggests that H3R antagonism might not only deliver symptomatic treatment in AD, but also possess disease-modifying benefits (Bitner et al., 2011). The gene discussed is HRH3; the disease is Alzheimer disease.